辛伐他汀对血脂正常的急性冠脉综合征患者炎症因子及预后的影响

The effects of simvastatin on inflammation facrors in patients with mean serum lipid in acute coronary artery syndrome(ACS)

目的观察血脂正常的急性冠脉综合征(ACS)早期应用辛伐他汀对C反应蛋白(CRP)及心血管事件发生的影响。方法将64例血脂正常的急性冠脉综合征患者随机分为治疗组(n=32除常规治疗外加服辛伐他汀20mg)和对照组(n=32仅常规治疗),于治疗前、治疗4w后观察C反应蛋白变化,心血管事件发生次数。结果治疗组于治疗后CRP有明显下降(1.76mg/L对2.11mg/L,P<0.05),并明显低于对照组(1.76mg/L对2.08mg/L,P<0.05),心血管事件也明显少于对照组(9.4%对31.3%,P<0.05)。结论辛伐他汀对血脂正常的ACS早期治疗能明显降低CRP水平,抑制炎症反应,稳定易损斑块,减少心血管事件的发生。

Objective To evaluate the effection of Simvastatin on C-reactive protein （CRP） and the cardiovascular attacts in the patients with ACS,however,without dyslipidemia. Method A cohort of 64 patients with ACS but mean serum lipid was randomly assigned to Simvastatin group （n=32 Simvastatin 20mg based on routine treatment） and control group （n=32 only received routine treatment）. Recorded the change of CRP and number of cadouvascular attacts before and 4 weeks after treatment. Results CRP in Simvastatin group significantly decreased （1.76mg/L vas 2.11mg/L,P〈0.05） after treatment and obviously lower than control group（1.76mg/L vas 2.08mg/L,P〈0.05）,and the cadiovascular attacts （9.4% vas 31.3%,P〈0.05） decreased obviously. Conclussion Simvastatin namely to decrease CPR level,inhibite inflammation reactions,stable the Vulnerable plaque,reduce the cadiovaseular attacts in the ACS early application with mean serum lipid.